Pfizer R&D
Executive Summary
Once-daily oral antibiotic azithromycin and the broad spectrum oral anti-fungal fluconazole are scheduled for 1989 regulatory filings, firm reports to securities analysts. A third compound, CP 66,248, represents "a new family of corticosteroid-like efficacy properties in arthritis patients," Pfizer said. "It appears to act by modifying interleukin-1 mediate processes in the inflamed joint".